RecruitingNCT02734277

Type 1 Diabetes Extension Study

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment

111 participants

Start Date

Aug 18, 2016

Study Type

OBSERVATIONAL

Conditions

Type 1 Diabetes Mellitus T1D T1DM

Summary

This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.

Eligibility

Min Age: 8 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term follow-up study for people who previously participated in a clinical trial studying immune tolerance treatments for Type 1 diabetes, aiming to understand how participants' health has changed over time. **You may be eligible if...** - You previously participated in a Type 1 diabetes study approved by the Immune Tolerance Network - You are able to give informed consent (or assent, if you are a child) **You may NOT be eligible if...** - You have a medical condition that would make it unsafe for you to participate - You are unable to attend the required study visits or complete the assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(12)

UCSF School of Medicine

San Francisco, California, United States

Stanford University

Stanford, California, United States

University of Colorado School of Medicine: Barbara Davis Center for Diabetes

Aurora, Colorado, United States

Yale University

New Haven, Connecticut, United States

Emory University

Atlanta, Georgia, United States

Indiana University Riley Hospital for Children

Indianapolis, Indiana, United States

University of Iowa Health Care Division of Pediatric Endocrinology

Iowa City, Iowa, United States

Joslin Diabetes Center

Boston, Massachusetts, United States

University of Minnesota

Minneapolis, Minnesota, United States

Children's Mercy Hospital

Kansas City, Missouri, United States

Sanford Research

Sioux Falls, South Dakota, United States

Benaroya Research Institute

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02734277

Related Trials

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068141 locations

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

NCT075489961 location

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

NCT0722432110 locations

Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus

NCT0670467216 locations

A Study of GNTI-122 in Adults Recently Diagnosed With T1D

NCT0691935410 locations